ERBB2 and heart failure: It is also interesting to note that prophylactic heart failure therapy was associated with a clinically important reduction in HER2 therapy interruptions, suggesting that there is a subgroup of patients unable to proceed with therapy despite not fulfilling the criteria for cardiotoxicity, perhaps due to symptomatic heart failure with a sub-threshold decline in LVEF.